A Phase 4 interventional study of Placebo plus standard therapy and Belimumab 10 mg/kg plus standard therapy in Systemic Lupus Erythematosus, sponsored by Human Genome Sciences Inc., a GSK Company. Completed at 96 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-08.
Sponsored by Human Genome Sciences Inc., a GSK Company (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 7th largest by enrollment, is one of 2 that started in 2013, is one of 10 in phase 4, and was the 15th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Nanjing University School of Medicine · Sites in China
Ages 14–65
National University Hospital, Singapore · Sites in Singapore
Ages 21–70
First Affiliated Hospital Xi'an Jiaotong University
Ages 18+
By country, each count listing its studies:
belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 503 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 81 across the 36 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Human Genome Sciences Inc., a GSK Company, one of the names counted as GlaxoSmithKline. Under that name alone:
Human Genome Sciences Inc., a GSK Company is the lead sponsor of 13 studies on the registry; none are open to participants now.
43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline: 1 open now, 4 under way, none of them phase 3. Of 36 finished, 26 (72%) have results posted.
Among the 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline, this one is the 7th largest by enrollment of the 36 interventional ones that give a count, is one of 5 that started in 2013, is one of 5 in phase 4, and was the 20th registered.
GlaxoSmithKline’s Lupus Erythematosus, Systemic studies by the year they started, since 2002.
2 of the studies testing belimumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340463Nanjing University School of MedicineThe Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment | 2027-06 |
| NCT06411249GlaxoSmithKlineA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | 2027-06-29 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, from their registry updates:
Among GlaxoSmithKline’s 43 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients of black race with systemic lupus erythematosus (SLE; lupus).
Study participants receive stable standard therapy for lupus in addition to receiving either placebo (no active medicine) or belimumab. The controlled period of the study is 52 weeks. The random assignment in this study is "2 to 1" which means that for every 3 participants, 2 will receive belimumab and 1 will receive placebo. Participants who successfully complete the 52-week study may enter into a 6-month open-label extension. All participants in the open-label extension receive belimumab plus standard therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have 2 unequivocally positive autoantibody test results defined as a positive antinuclear antibody (ANA) test [i.e., titer >= 1:80 by human epithelial cell line 2 (HEp-2) immunofluorescence assay (IFA) and/or positive enzyme immunoassay (EIA)] and/or a positive anti- double stranded deoxyribonucleic acid (dsDNA) (>= 30 international units [IU]/milliliter [mL]) serum antibody test as follows:
Historical documentation of a positive ANA test (e.g., HEp-2 IFA or EIA) or anti-dsDNA (eg, anti-dsDNA by any validated commercial assay) must include the date and type of the test, the name of the testing laboratory, numerical reference range, and a key that explains values provided as positive versus negative OR negative, equivocal/borderline positive). Only unequivocally positive values as defined in the laboratory's reference range are acceptable; borderline values will not be accepted.
On a stable SLE treatment regimen consisting of any of the following medications (alone or in combination) for a period of at least 30 days prior to Day 0 (i.e., day of 1st dose of study agent):
Note:
A female subject is eligible to enter the study if she is:
Exclusion criteria:
Have received any of the following within 364 days of Day 0:
Have received any of the following within 90 days of Day 0:
Have received any of the following within 60 days of Day 0:
Have received any of the following within 30 days of Day 0:
Have required management of acute or chronic infections, as follows:
Severity grading tables except for the following that are allowed:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kilogram (kg) IV every 28 days for an additional 6 months.
Biological: Placebo plus standard therapy · Drug: Standard therapy
Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
Biological: Belimumab 10 mg/kg plus standard therapy · Drug: Standard therapy
Placebo plus standard therapy
Drug page: Belimumab
Belimumab 10mg/kg plus standard therapy
Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index (SRI) Response Rate With the Modified Systemic Lupus Erythematosus Disease Activity Index- 2K (SLEDAI-2K) Scoring for Proteinuria at Week 52 [DB Phase]
SRI response is defined as \>=4 point reduction, from Baseline in safety of estrogen in Lupus National Assessment(SELENA)SLEDAI\[SS\] score (with modified SLEDAI-2K scoring for proteinuria \[PU\]), no worsening (increase of \<0.30 points from Baseline) in Physician's Global Assessment (PGA) and no new British Isles Lupus Assessment Group of SLE clinics(BILAG)A organ domain score \[ODS\] or 2 new BILAG B ODS compared with Baseline. Drop-outs and treatment failures were set to non-responders. Analysis performed using a logistic regression model for comparison between belimumab and placebo with covariates treatment group, Baseline SS score (with modified SLEDAI-2K scoring for PU) (\<=9 versus \[vs.\] \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and region (United States \[US\]/Canada vs. Rest of World). The Modified Intention-To-Treat (mITT) population comprised of safety population excluding participants who had any assessment at 3 sites (202196, 202513 or 107286).
Time frame: Week 52
Percentage of Participants Achieving a SRI Response Rate With the Modified SLEDAI-2K Scoring for Proteinuria at Week 24 of OL Phase
SRI response is defined as \>=4 point reduction, from OL Baseline in SS score (with the modified SLEDAI-2K scoring for PU), no worsening (increase of \<0.30 points from OL Baseline) in PGA and no new BILAG A ODS or 2 new BILAG B ODS compared with OL Baseline. For participants switching from placebo to belimumab 10 mg/kg IV in the OL phase, Baseline was defined as the last assessment at the end of the double-blind phase (i.e. Week 52) pre-OL treatment. For participants that received belimumab 10 mg/kg IV during the double-blind phase and continued to receive belimumab 10 mg/kg IV during the OL phase, Baseline was defined as Day 1 of the double-blind phase.
Time frame: Week 24 of OL phase (Week 76)
Number of Participants With Non-serious Adverse Events (nSAEs) and Serious Adverse Event (SAEs) [OL Phase]
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. Number of participants who had common nSAEs (\>=5%) and any SAEs are presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).
Time frame: Week 52 to Week 84
Number of Participants With Severe AEs [OL Phase]
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with severe AEs have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).
Time frame: Week 52 to Week 84
Number of Participants With AEs Leading to Treatment Discontinuation [OL Phase]
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to treatment discontinuation have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).
Time frame: Week 52 to Week 84
Number of Participants With Worst Toxicity Grade 3 or 4 for Hematology Parameters [OL Phase]
Blood samples were collected for the assessment of hematology parameters. The parameters assessed were activated partial thromboplastin time (APTT), hemoglobin, leukocytes, neutrophils, platelets and prothrombin time. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life-threatening (Grade 4) according to Division of Microbiology and Infectious Diseases (DMID \[Modified from DMID Adult Toxicity Tables, 2001\]) AE Severity Grading. Number of participants with worst toxicity Grade 3 or 4 for hematology parameters have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).
Time frame: Week 52 to Week 84
Number of Participants With Worst Toxicity Grade of 3 or 4 for Clinical Chemistry Parameters [OL Phase]
Blood samples were collected for the assessment of liver function and other chemistry parameters. The parameters assessed were alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), bilirubin, albumin, creatinine, hyperglycemia, hypoglycemia and urate. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life-threatening (Grade 4) according to DMID AE Severity Grading. Number of participants with worst toxicity Grade of 3 or 4 for liver function and other chemistry parameters have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).
Time frame: Week 52 to Week 84
Number of Participants With Worst Toxicity Grade of 3 or 4 for Urinalysis Parameters [OL Phase]
Urinalysis parameters assessed were urine protein and protein/creatinine. Urine samples were collected for the measurement of urinalysis parameters by dipstick method. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life-threatening (Grade 4) according to DMID AE Severity Grading. Number of participants with worst toxicity grade of 3 or 4 for urinalysis parameters have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).
Time frame: Week 52 to Week 84
Number of Participants With Worst Toxicity Grade of 3 or 4 of Immunoglobulins [OL Phase]
Serum samples were obtained for the measurement of immunoglobulin G. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening (Grade 4) according to DMID AE Severity Grading. Number of participants with worst toxicity grade of 3 or 4 of immunoglobulin G have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).
Time frame: Week 52 to Week 84
Percentage of Participants Achieving SRI-SS Response Rate at Week 52 [DB Phase]
SRI is defined as \>=4 point reduction, from Baseline in SS score, no worsening (increase of \<0.30 points from Baseline) in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with Baseline. Drop-outs and Treatment failures were set to non-responders. Analysis was performed using a logistic regression model for the comparison between belimumab and placebo with covariates treatment group, Baseline SS score (\<=9 vs. \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and region (US/Canada vs. Rest of World).
Time frame: Week 52
Percentage of Participants Achieving SRI-SS Response Rate With the SELENA SLEDAI for Scoring of Proteinuria at Week 24 of OL Phase
SRI response is defined as \>=4 point reduction, from OL Baseline in SS scoring for PU, no worsening (increase of \<0.30 points from OL Baseline) in PGA and no new BILAG A ODS or 2 new BILAG B ODS compared with OL Baseline. For participants switching from placebo to belimumab 10 mg/kg IV in the open-label phase, Baseline was defined as the last assessment at the end of the double-blind phase (i.e. Week 52) pre-OL treatment. For participants that received belimumab 10 mg/kg IV during the double-blind phase and continued to receive belimumab 10 mg/kg IV during the open-label phase, Baseline was defined as Day 1 of the double-blind phase.
Time frame: Week 24 of OL phase (Week 76)
Time to First Severe Flare (as Measured by the Modified SLE Flare Index) up to 52 Weeks [DB Phase]
Time to first severe SLE flare is defined as the number of days from treatment start date until the participant met an event (event date - treatment start date +1). Analyses of severe SLE flare was performed on modified SS SLE flare index that excludes severe flares (SF) that were triggered only by an increase in SS score to \>12 (this may only represent a modest increase in disease activity). Treatment failures were imputed as SF. For participants who died, data were censored at date of death if no SF occurred before death. Only post-Baseline SF were considered. Analysis was performed using Cox proportional hazards model for the comparison between belimumab and placebo adjusting for Baseline SS-S2K score (\<=9 vs. \>=10), baseline complement levels (at least 1 C3/C4 low vs. no C3/C4 low), and region (US/Canada vs. Rest of World). Median and inter-Quartile range (1st and 3rd Quartiles) have been presented.
Time frame: Up to 52 Weeks
Time to First Severe Flare (as Measured by the Modified SLE Flare Index) [OL Phase]
Time to first severe SLE flare is defined as the number of days from OL treatment start date until the participant met an event (event date - OL treatment start date +1). Analyses of severe SLE flare was performed on modified SS SLE flare index that excludes SF that were triggered only by an increase in SS score to \>12. For participants who died, data were censored at date of death if no SF occurred before death. Only post first OL treatment SF were considered. Median and inter-Quartile range (25th and 75th percentile) have been presented.
Time frame: Up to Week 24 of OL Phase (Week 76)
Percent of Participants Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Week 40 Through 52, in Participants Receiving Greater Than 7.5 mg/Day at Baseline [DB Phase]
Average (avg.) daily prednisone (PRED.) dose was calculated taking into account all steroids taken intravenously, intramuscularly, subcutaneously, intradermally and orally for both Systemic Lupus Erythema (SLE) and non-SLE reasons. A responder was defined as having a PRED. reduction \[REDN.\] by \>=25% from Baseline to \<=7.5 mg/day during Weeks 40 through 52. Drop-outs and Treatment failures were imputed as having no REDN. in PRED. (if Baseline PRED. \>7.5 mg/day). At Baseline, the avg. daily prednisone dose \[PD\] was the sum of all PDs over 7 consecutive days \[excluding Day 0\], divided (DIV.) by 7. For analysis, the avg. PD was the total PD during Weeks 40 through 52 DIV. by the number of days during Weeks 40 through 52. Analysis was performed using a logistic regression model with covariates treatment group, Baseline PD, Baseline SS-S2K score, (\<=9 vs \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and region (US/Canada vs. Rest of World).
Time frame: Baseline and Week 40 through Week 52
Percent of Participants Whose Average Prednisone Dose Had Been Reduced to <=7.5 mg/Day in Participants Receiving Greater Than 7.5 mg/Day at Pre-belimumab Baseline (at Week 28 of OL Phase)
Average daily prednisone dose was calculated taking into account all steroids taken intravenously, intramuscularly, subcutaneously, intradermally and orally for both SLE and non-SLE reasons. A responder was defined as a participant who decreased their daily prednisone dose to \<=7.5 mg/day from an OL Baseline dose \>7.5 mg/day. The OL Baseline was defined as the last available value prior to the initiation of treatment with belimumab. The average daily prednisone dose was the sum of all PDs over 7 consecutive days including OL Week 28 divided by 7. Only those participants with data available at the specified data points were analyzed.
Time frame: OL Baseline and Week 28 of OL Phase (Week 80)
Number of Participants With nSAEs and SAEs [DB Phase]
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. Safety population was defined as all participants who were randomized and treated with at least one dose of study treatment. Number of participants who had common nSAEs (\>=5%) and any SAEs are presented.
Time frame: Up to 52 Weeks
Number of Participants With Severe AEs [DB Phase]
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with severe AEs have been presented.
Time frame: Up to 52 Weeks
Number of Participants With AEs Leading to Treatment Discontinuation [DB Phase]
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to treatment discontinuation have been presented.
Time frame: Up to 52 Weeks
Number of Participants With Worst Toxicity Grade 3 or 4 for Hematology Parameters [DB Phase]
Blood samples were collected for the assessment of hematology parameters up to 52 Weeks. The parameters assessed were APTT, hemoglobin, leukocytes, neutrophils, platelets and prothrombin time. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening according to DMID AE Severity Grading. Number of participants with worst toxicity Grade of 3 or 4 for hematology parameters have been presented.
Time frame: Up to 52 weeks
Number of Participants With Worst Toxicity Grade of 3 or 4 for Clinical Chemistry Parameters [DB Phase]
Blood samples were collected for the assessment of liver function and other chemistry parameters up to 52 Weeks. The parameters assessed were ALT, AST, GGT, albumin, hyperglycemia and hypoglycemia. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening according to DMID AE Severity Grading. Only those participants with worst toxicity Grade of 3 or 4 for other chemistry parameters have been presented.
Time frame: Up to 52 weeks
Number of Participants With Worst Toxicity Grade of 3 or 4 for Urinalysis Parameters [DB Phase]
Urinalysis parameters assessed were urine protein and protein/creatinine. Urine samples were collected for the measurement of urinalysis parameters by dipstick method up to 52 Weeks. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening according to DMID AE Severity Grading. Only those participants with worst toxicity grade of 3 or 4 for urinalysis parameters have been presented.
Time frame: Up to 52 weeks
This study evaluated the efficacy and safety of belimumab compared with placebo in adult participants with Systemic Lupus Erythematosus (SLE). This was a multicenter study conducted at United States (88 centers), United Kingdom (6), South Africa (5), France (4), Columbia (6) and Brazil (18).
| Milestone | Placebo to Belimumab 10 mg/kg | Belimumab 10 mg/kg to Belimumab 10 mg/kg |
|---|---|---|
| Started | 165 | 331 |
| Completed | 121 | 252 |
| Not completed | 44 | 79 |
| Withdrew: Site closed | 3 | 5 |
| Withdrew: Protocol violation | 2 | 6 |
| Withdrew: Lost to follow-up | 1 | 8 |
| Withdrew: Physician decision | 9 | 12 |
| Withdrew: Lack of efficacy | 9 | 15 |
| Withdrew: Withdrawal by subject | 10 | 14 |
| Withdrew: Adverse event | 10 | 19 |
| Milestone | Placebo to Belimumab 10 mg/kg | Belimumab 10 mg/kg to Belimumab 10 mg/kg |
|---|---|---|
| Started | 117 | 242 |
| Completed | 107 | 220 |
| Not completed | 10 | 22 |
| Withdrew: Withdrawal by subject | 5 | 2 |
| Withdrew: Physician decision | 1 | 4 |
| Withdrew: Lost to follow-up | 1 | 4 |
| Withdrew: Site closed | 2 | 8 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Adverse event | 1 | 0 |
SRI response is defined as \>=4 point reduction, from Baseline in safety of estrogen in Lupus National Assessment(SELENA)SLEDAI\[SS\] score (with modified SLEDAI-2K scoring for proteinuria \[PU\]), no worsening (increase of \<0.30 points from Baseline) in Physician's Global Assessment (PGA) and no new British Isles Lupus Assessment Group of SLE clinics(BILAG)A organ domain score \[ODS\] or 2 new BILAG B ODS compared with Baseline. Drop-outs and treatment failures were set to non-responders. Analysis performed using a logistic regression model for comparison between belimumab and placebo with covariates treatment group, Baseline SS score (with modified SLEDAI-2K scoring for PU) (\<=9 versus \[vs.\] \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and region (United States \[US\]/Canada vs. Rest of World). The Modified Intention-To-Treat (mITT) population comprised of safety population excluding participants who had any assessment at 3 sites (202196, 202513 or 107286).
| Percentage of participants | Placebo (DB Phase) | Belimumab 10 mg/kg (DB Phase) |
|---|---|---|
| Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index (SRI) Response Rate With the Modified Systemic Lupus Erythematosus Disease Activity Index- 2K (SLEDAI-2K) Scoring for Proteinuria at Week 52 [DB Phase] | 41.6 | 48.7 |
SRI response is defined as \>=4 point reduction, from OL Baseline in SS score (with the modified SLEDAI-2K scoring for PU), no worsening (increase of \<0.30 points from OL Baseline) in PGA and no new BILAG A ODS or 2 new BILAG B ODS compared with OL Baseline. For participants switching from placebo to belimumab 10 mg/kg IV in the OL phase, Baseline was defined as the last assessment at the end of the double-blind phase (i.e. Week 52) pre-OL treatment. For participants that received belimumab 10 mg/kg IV during the double-blind phase and continued to receive belimumab 10 mg/kg IV during the OL phase, Baseline was defined as Day 1 of the double-blind phase.
| Percentage of participants | Placebo to Belimumab 10 mg/kg (OL Phase) | Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) |
|---|---|---|
| Percentage of Participants Achieving a SRI Response Rate With the Modified SLEDAI-2K Scoring for Proteinuria at Week 24 of OL Phase | 18.8 | 73.6 |
An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. Number of participants who had common nSAEs (\>=5%) and any SAEs are presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).
| Participants | Placebo to Belimumab 10 mg/kg (OL Phase) | Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) |
|---|---|---|
| nSAEs | 23 | 49 |
| SAEs | 6 | 13 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with severe AEs have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).
| Participants | Placebo to Belimumab 10 mg/kg (OL Phase) | Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) |
|---|---|---|
| Number of Participants With Severe AEs [OL Phase] | 10 | 9 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to treatment discontinuation have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).
| Participants | Placebo to Belimumab 10 mg/kg (OL Phase) | Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) |
|---|---|---|
| Number of Participants With AEs Leading to Treatment Discontinuation [OL Phase] | 1 | 0 |
Blood samples were collected for the assessment of hematology parameters. The parameters assessed were activated partial thromboplastin time (APTT), hemoglobin, leukocytes, neutrophils, platelets and prothrombin time. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life-threatening (Grade 4) according to Division of Microbiology and Infectious Diseases (DMID \[Modified from DMID Adult Toxicity Tables, 2001\]) AE Severity Grading. Number of participants with worst toxicity Grade 3 or 4 for hematology parameters have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).
| Participants | Placebo to Belimumab 10 mg/kg (OL Phase) | Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) |
|---|---|---|
| APTT, Grade 3, n=93,203 | 0 | 1 |
| APTT, Grade 4, n=93,203 | 0 | 0 |
| Hemoglobin, Grade 3, n=115,235 | 4 | 6 |
| Hemoglobin, Grade 4, n=115,235 | 0 | 0 |
| Leukocytes, Grade 3, n=114,235 | 0 | 6 |
| Leukocytes, Grade 4, n=114,235 | 0 | 0 |
| Neutrophils, Grade 3, n=114,234 | 2 | 6 |
| Neutrophils, Grade 4, n=114,234 | 0 | 1 |
| Platelets, Grade 3, n=115,235 | 0 | 0 |
| Platelets, Grade 4, n=115,235 | 0 | 0 |
| Prothrombin time, Grade 3, n=93, 204 | 3 | 2 |
| Prothrombin time, Grade 4, n=93, 204 | 1 | 3 |
Blood samples were collected for the assessment of liver function and other chemistry parameters. The parameters assessed were alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), bilirubin, albumin, creatinine, hyperglycemia, hypoglycemia and urate. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life-threatening (Grade 4) according to DMID AE Severity Grading. Number of participants with worst toxicity Grade of 3 or 4 for liver function and other chemistry parameters have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).
| Participants | Placebo to Belimumab 10 mg/kg (OL Phase) | Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) |
|---|---|---|
| ALP, Grade 3 | 0 | 0 |
| ALP, Grade 4 | 0 | 0 |
| ALT, Grade 3 | 0 | 0 |
| ALT, Grade 4 | 0 | 0 |
| AST, Grade 3 | 0 | 0 |
| AST, Grade 4 | 0 | 0 |
| Bilirubin, Grade 3 | 0 | 0 |
| Bilirubin, Grade 4 | 0 | 0 |
| GGT, Grade 3 | 0 | 1 |
| GGT, Grade 4 | 0 | 0 |
| Albumin, Grade 3 | 0 | 2 |
| Albumin, Grade 4 | 1 | 0 |
| Creatinine, Grade 3 | 0 | 0 |
| Creatinine, Grade 4 | 0 | 0 |
| Hypoglycemia, Grade 3 | 0 | 0 |
| Hypoglycemia, Grade 4 | 0 | 0 |
| Hyperglycemia, Grade 3 | 1 | 4 |
| Hyperglycemia, Grade 4 | 0 | 0 |
| Urate, Grade 3 | 0 | 0 |
| Urate, Grade 4 | 0 | 0 |
Urinalysis parameters assessed were urine protein and protein/creatinine. Urine samples were collected for the measurement of urinalysis parameters by dipstick method. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life-threatening (Grade 4) according to DMID AE Severity Grading. Number of participants with worst toxicity grade of 3 or 4 for urinalysis parameters have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).
| Participants | Placebo to Belimumab 10 mg/kg (OL Phase) | Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) |
|---|---|---|
| Protein, Grade 3, n=115, 234 | 0 | 0 |
| Protein, Grade 4, n=115,234 | 0 | 0 |
| Protein/Creatinine, Grade 3,n=112,227 | 5 | 5 |
| Protein/Creatinine, Grade 4, n=112,227 | 3 | 0 |
Serum samples were obtained for the measurement of immunoglobulin G. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening (Grade 4) according to DMID AE Severity Grading. Number of participants with worst toxicity grade of 3 or 4 of immunoglobulin G have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).
| Participants | Placebo to Belimumab 10 mg/kg (OL Phase) | Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) |
|---|---|---|
| Grade 3 | 0 | 1 |
| Grade 4 | 0 | 0 |
SRI is defined as \>=4 point reduction, from Baseline in SS score, no worsening (increase of \<0.30 points from Baseline) in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with Baseline. Drop-outs and Treatment failures were set to non-responders. Analysis was performed using a logistic regression model for the comparison between belimumab and placebo with covariates treatment group, Baseline SS score (\<=9 vs. \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and region (US/Canada vs. Rest of World).
| Percentage of participants | Placebo (DB Phase) | Belimumab 10 mg/kg (DB Phase) |
|---|---|---|
| Percentage of Participants Achieving SRI-SS Response Rate at Week 52 [DB Phase] | 41.6 | 49.0 |
SRI response is defined as \>=4 point reduction, from OL Baseline in SS scoring for PU, no worsening (increase of \<0.30 points from OL Baseline) in PGA and no new BILAG A ODS or 2 new BILAG B ODS compared with OL Baseline. For participants switching from placebo to belimumab 10 mg/kg IV in the open-label phase, Baseline was defined as the last assessment at the end of the double-blind phase (i.e. Week 52) pre-OL treatment. For participants that received belimumab 10 mg/kg IV during the double-blind phase and continued to receive belimumab 10 mg/kg IV during the open-label phase, Baseline was defined as Day 1 of the double-blind phase.
| Percentage of participants | Placebo to Belimumab 10 mg/kg (OL Phase) | Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) |
|---|---|---|
| Percentage of Participants Achieving SRI-SS Response Rate With the SELENA SLEDAI for Scoring of Proteinuria at Week 24 of OL Phase | 19.4 | 73.1 |
Time to first severe SLE flare is defined as the number of days from treatment start date until the participant met an event (event date - treatment start date +1). Analyses of severe SLE flare was performed on modified SS SLE flare index that excludes severe flares (SF) that were triggered only by an increase in SS score to \>12 (this may only represent a modest increase in disease activity). Treatment failures were imputed as SF. For participants who died, data were censored at date of death if no SF occurred before death. Only post-Baseline SF were considered. Analysis was performed using Cox proportional hazards model for the comparison between belimumab and placebo adjusting for Baseline SS-S2K score (\<=9 vs. \>=10), baseline complement levels (at least 1 C3/C4 low vs. no C3/C4 low), and region (US/Canada vs. Rest of World). Median and inter-Quartile range (1st and 3rd Quartiles) have been presented.
| Days | Placebo (DB Phase) | Belimumab 10 mg/kg (DB Phase) |
|---|---|---|
| Time to First Severe Flare (as Measured by the Modified SLE Flare Index) up to 52 Weeks [DB Phase] | NA (346 to NA) | NA (NA to NA) |
Time to first severe SLE flare is defined as the number of days from OL treatment start date until the participant met an event (event date - OL treatment start date +1). Analyses of severe SLE flare was performed on modified SS SLE flare index that excludes SF that were triggered only by an increase in SS score to \>12. For participants who died, data were censored at date of death if no SF occurred before death. Only post first OL treatment SF were considered. Median and inter-Quartile range (25th and 75th percentile) have been presented.
| Days | Placebo to Belimumab 10 mg/kg (OL Phase) | Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) |
|---|---|---|
| Time to First Severe Flare (as Measured by the Modified SLE Flare Index) [OL Phase] | NA (NA to NA) | 232 (232 to NA) |
Average (avg.) daily prednisone (PRED.) dose was calculated taking into account all steroids taken intravenously, intramuscularly, subcutaneously, intradermally and orally for both Systemic Lupus Erythema (SLE) and non-SLE reasons. A responder was defined as having a PRED. reduction \[REDN.\] by \>=25% from Baseline to \<=7.5 mg/day during Weeks 40 through 52. Drop-outs and Treatment failures were imputed as having no REDN. in PRED. (if Baseline PRED. \>7.5 mg/day). At Baseline, the avg. daily prednisone dose \[PD\] was the sum of all PDs over 7 consecutive days \[excluding Day 0\], divided (DIV.) by 7. For analysis, the avg. PD was the total PD during Weeks 40 through 52 DIV. by the number of days during Weeks 40 through 52. Analysis was performed using a logistic regression model with covariates treatment group, Baseline PD, Baseline SS-S2K score, (\<=9 vs \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and region (US/Canada vs. Rest of World).
| Percentage of participants | Placebo (DB Phase) | Belimumab 10 mg/kg (DB Phase) |
|---|---|---|
| Percent of Participants Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Week 40 Through 52, in Participants Receiving Greater Than 7.5 mg/Day at Baseline [DB Phase] | 12.6 | 14.7 |
Average daily prednisone dose was calculated taking into account all steroids taken intravenously, intramuscularly, subcutaneously, intradermally and orally for both SLE and non-SLE reasons. A responder was defined as a participant who decreased their daily prednisone dose to \<=7.5 mg/day from an OL Baseline dose \>7.5 mg/day. The OL Baseline was defined as the last available value prior to the initiation of treatment with belimumab. The average daily prednisone dose was the sum of all PDs over 7 consecutive days including OL Week 28 divided by 7. Only those participants with data available at the specified data points were analyzed.
| Percentage of participants | Placebo to Belimumab 10 mg/kg (OL Phase) | Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) |
|---|---|---|
| Percent of Participants Whose Average Prednisone Dose Had Been Reduced to <=7.5 mg/Day in Participants Receiving Greater Than 7.5 mg/Day at Pre-belimumab Baseline (at Week 28 of OL Phase) | 14.8 | 31.9 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. Safety population was defined as all participants who were randomized and treated with at least one dose of study treatment. Number of participants who had common nSAEs (\>=5%) and any SAEs are presented.
| Participants | Placebo (DB Phase) | Belimumab 10 mg/kg (DB Phase) |
|---|---|---|
| nSAE | 77 | 196 |
| SAE | 31 | 36 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with severe AEs have been presented.
| Participants | Placebo (DB Phase) | Belimumab 10 mg/kg (DB Phase) |
|---|---|---|
| Number of Participants With Severe AEs [DB Phase] | 37 | 46 |
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to treatment discontinuation have been presented.
| Participants | Placebo (DB Phase) | Belimumab 10 mg/kg (DB Phase) |
|---|---|---|
| Number of Participants With AEs Leading to Treatment Discontinuation [DB Phase] | 12 | 22 |
Blood samples were collected for the assessment of hematology parameters up to 52 Weeks. The parameters assessed were APTT, hemoglobin, leukocytes, neutrophils, platelets and prothrombin time. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening according to DMID AE Severity Grading. Number of participants with worst toxicity Grade of 3 or 4 for hematology parameters have been presented.
| Participants | Placebo (DB Phase) | Belimumab 10 mg/kg (DB Phase) |
|---|---|---|
| APTT, Grade 3, n=159,318 | 0 | 3 |
| APTT, Grade 4, n=159,318 | 0 | 2 |
| Hemoglobin, Grade 3, n=161,327 | 5 | 15 |
| Hemoglobin, Grade 4, n=161,327 | 1 | 0 |
| Leukocytes, Grade 3, n=161,327 | 3 | 17 |
| Leukocytes, Grade 4, n=161,327 | 1 | 0 |
| Neutrophils, Grade 3, n=161,327 | 9 | 28 |
| Neutrophils, Grade 4, n=161,327 | 1 | 5 |
| Platelets, Grade 3, n=161,327 | 1 | 1 |
| Platelets, Grade 4, n=161,327 | 0 | 1 |
| Prothrombin time, Grade 3, n=159, 318 | 8 | 10 |
| Prothrombin time, Grade 4, n=159,318 | 2 | 6 |
Blood samples were collected for the assessment of liver function and other chemistry parameters up to 52 Weeks. The parameters assessed were ALT, AST, GGT, albumin, hyperglycemia and hypoglycemia. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening according to DMID AE Severity Grading. Only those participants with worst toxicity Grade of 3 or 4 for other chemistry parameters have been presented.
| Participants | Placebo (DB Phase) | Belimumab 10 mg/kg (DB Phase) |
|---|---|---|
| ALT, Grade 3 | 0 | 2 |
| AST, Grade 3 | 0 | 2 |
| GGT, Grade 3 | 6 | 6 |
| GGT, Grade 4 | 0 | 1 |
| Albumin, Grade 3 | 5 | 3 |
| Albumin, Grade 4 | 1 | 1 |
| Hyperglycemia, Grade 3 | 4 | 7 |
| Hyperglycemia, Grade 4 | 1 | 1 |
| Hypoglycemia, Grade 3 | 0 | 4 |
| Hypoglycemia, Grade 4 | 3 | 1 |
Urinalysis parameters assessed were urine protein and protein/creatinine. Urine samples were collected for the measurement of urinalysis parameters by dipstick method up to 52 Weeks. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening according to DMID AE Severity Grading. Only those participants with worst toxicity grade of 3 or 4 for urinalysis parameters have been presented.
| Participants | Placebo (DB Phase) | Belimumab 10 mg/kg (DB Phase) |
|---|---|---|
| Protein, Grade 3, n=161, 324 | 0 | 1 |
| Protein/creatinine, Grade 3,n=161,322 | 8 | 25 |
| Protein/creatinine, Grade 4, n=161,322 | 12 | 11 |
Collected over nSAEs and SAEs were collected from the start of study treatment up to Week 52 for Double Blind phase and from Week 52 to Week 84 for the Open Label phase. Participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (DB Phase) | 0/165 (0%) | 31/165 (18.8%) | 77/165 (46.7%) |
| Belimumab 10 mg/kg (DB Phase) | 2/331 (0.6%) | 36/331 (10.9%) | 196/331 (59.2%) |
| Placebo to Belimumab 10 mg/kg (OL Phase) | 0/117 (0%) | 6/117 (5.1%) | 23/117 (19.7%) |
| Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) | 0/242 (0%) | 13/242 (5.4%) | 49/242 (20.2%) |
| Event | Placebo (DB Phase) | Belimumab 10 mg/kg (DB Phase) | Placebo to Belimumab 10 mg/kg (OL Phase) | Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 6/165 | 2/331 | 0/117 | 2/242 |
| PericarditisCardiac disorders | 3/165 | 0/331 | 0/117 | 0/242 |
| Lupus nephritisRenal and urinary disorders | 2/165 | 1/331 | 0/117 | 0/242 |
| Urinary tract infectionInfections and infestations | 2/165 | 0/331 | 0/117 | 0/242 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 1/165 | 3/331 | 0/117 | 1/242 |
| Acute myocardial infarctionCardiac disorders | 0/165 | 1/331 | 1/117 | 0/242 |
| AnaemiaBlood and lymphatic system disorders | 0/165 | 1/331 | 1/117 | 0/242 |
| Atrial fibrillationCardiac disorders | 1/165 | 0/331 | 1/117 | 0/242 |
| Cerebrovascular accidentNervous system disorders | 0/165 | 1/331 | 1/117 | 0/242 |
| SyncopeNervous system disorders | 0/165 | 0/331 | 1/117 | 1/242 |
| Event | Placebo (DB Phase) | Belimumab 10 mg/kg (DB Phase) | Placebo to Belimumab 10 mg/kg (OL Phase) | Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 14/165 | 48/331 | 4/117 | 20/242 |
| Urinary tract infectionInfections and infestations | 19/165 | 43/331 | 7/117 | 13/242 |
| HeadacheNervous system disorders | 18/165 | 39/331 | 0/117 | 0/242 |
| InfluenzaInfections and infestations | 17/165 | 28/331 | 7/117 | 16/242 |
| DiarrhoeaGastrointestinal disorders | 9/165 | 31/331 | 0/117 | 0/242 |
| NauseaGastrointestinal disorders | 15/165 | 18/331 | 0/117 | 0/242 |
| SinusitisInfections and infestations | 9/165 | 26/331 | 0/117 | 0/242 |
| InsomniaPsychiatric disorders | 10/165 | 18/331 | 0/117 | 0/242 |
| Back painMusculoskeletal and connective tissue disorders | 10/165 | 16/331 | 7/117 | 3/242 |
| VomitingGastrointestinal disorders | 7/165 | 19/331 | 0/117 | 0/242 |
| Age, Continuous(Years) | Placebo to Belimumab 10 mg/kg | Belimumab 10 mg/kg to Belimumab 10 mg/kg | Total |
|---|---|---|---|
| Mean | 39.5 ± 12.06 | 38.7 ± 11.00 | 38.9 ± 11.36 |
| Sex: Female, Male(Participants) | Placebo to Belimumab 10 mg/kg | Belimumab 10 mg/kg to Belimumab 10 mg/kg | Total |
|---|---|---|---|
| Female | 158 | 322 | 480 |
| Male | 7 | 9 | 16 |
| Race/Ethnicity, Customized(Participants) | Placebo to Belimumab 10 mg/kg | Belimumab 10 mg/kg to Belimumab 10 mg/kg | Total |
|---|---|---|---|
| Race — Black or African American | 165 | 331 | 496 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study is available via the Clinical Study Data Request site
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Feb 2013 to primary completion in Jun 2018, 63 months.
Results were first posted in Jul 2019, 1 year after primary completion.
Of 33 phase 4 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 42. This study's 63 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab
Lupus Erythematosus, Systemic →
Human Genome Sciences Inc., a GSK Company →